Millimed Holding, Inc. was founded in May 2004 to develop innovative treatment solutions surrounding vascular disease and advancements in endothelial management. The company has developed and is currently testing next generation alternatives for site specific drug/agent elution. Millimed plans to leverage its strong IP portfolio surrounding Nitric Oxide elution and develop nanospun coatings together with the incorporation of various drug elution mechanisms.